可降解微针针灸治疗干眼的多中心随机对照试验
该多中心、随机、阳性对照的关键性试验纳入224例干眼患者,1:1随机分为可降解微针针灸组与无菌针灸组,每周治疗3次共4周。结果显示微针组治疗相关不良事件比例显著更低(RR 0.17,95%CI 0.11-0.28,P<0.0001),且OSDI、VAS-SS及生活质量改善更明显。
要点
- 可降解微针针灸治疗干眼的不良事件风险显著低于无菌针灸。
- 微针组在OSDI、VAS-SS及生活质量评分上改善幅度更大。
- 微针组未出现皮肤过敏相关不良事件,无菌针灸组有发生。
核心结论
- 与无菌针灸相比,可降解微针针灸治疗干眼与更低治疗相关不良事件风险及更大临床改善相关。
研究设计与样本
- 多中心、随机、阳性对照的关键性试验,224例干眼患者按1:1随机分入可降解微针针灸组或无菌针灸组。
- 治疗为每周3次、共4周,取双侧8个穴位(GB14、TE23、EX-HN5、ST1)。
主要发现
- 可降解微针针灸组治疗相关不良事件比例显著低于无菌针灸组(风险比0.17;95%CI 0.11-0.28;P<0.0001)。
- 可降解微针针灸组OSDI改善优于无菌针灸组(均差-16.23;95%CI -19.32至-13.15)。
- 可降解微针针灸组VAS-SS改善优于无菌针灸组(均差-19.33;95%CI -22.00至-16.66)。
- 可降解微针针灸组生活质量改善优于无菌针灸组(均差0.96;95%CI 0.74-1.19)。
- 可降解微针针灸组未发生皮肤过敏相关不良事件,无菌针灸组有发生。
关键数值与推荐
- 主要结局为5周治疗期间经历至少一次治疗相关不良事件的患者比例。
- 次要结局包括OSDI、VAS-SS、生活质量评分、治疗满意度及额外安全性评估的变化。
- 试验注册号:KCT0008802(韩国Clinical Research Information Service)。
临床怎么用
- 对于干眼患者,可降解微针针灸可作为较无菌针灸安全性更高、临床改善更明显的治疗选择。
- 临床决策时可参考本试验中每周3次、共4周、取双侧GB14、TE23、EX-HN5、ST1的治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biodegradable microneedle acupuncture (BMA) is a novel technique designed to enhance therapeutic efficacy while minimizing adverse effects associated with conventional acupuncture. Dry eye (DE) is a common condition that significantly affects quality of life. This clinical trial aimed to assess the safety and efficacy of BMA compared to sterile acupuncture (SA) in treating DE. METHODS: A total of 224 participants with DE were randomly assigned in a 1:1 ratio to either the BMA group (BMAG) or the SA group (SAG). Treatment was administered three times per week for four weeks at eight bilateral acupoints (GB14, TE23, EX-HN5, and ST1). The primary outcome was the proportion of participants experiencing at least one treatment-related adverse event (AE) during the 5-week treatment period. Secondary outcomes included changes in the Ocular Surface Disease Index (OSDI), visual analog scale for subjective symptoms (VAS-SS), quality-of-life (QoL) scores, treatment satisfaction, and additional safety assessments. RESULTS: The proportion of participants experiencing treatment-related AEs was significantly lower in the BMAG than in the SAG (risk ratio, 0.17; 95% CI, 0.11-0.28; p < 0.0001). Greater improvements were observed in the BMAG for OSDI (mean difference -16.23; 95% confidence interval [CI], -19.32 to -13.15), VAS-SS (-19.33; 95% CI, -22.00 to -16.66), and QoL (0.96; 95% CI, 0.74-1.19). No skin allergy-related AEs occurred in the BMAG, whereas such events were observed in the SAG. CONCLUSIONS: BMA was associated with a lower risk of treatment-related AEs and greater clinical improvement compared with sterile acupuncture in patients with DE. These findings suggest that BMA may represent a safer and more effective therapeutic option for DE management. TRIAL REGISTRATION: Clinical Research Information Service, Republic of Korea (KCT0008802).
引用
- Park SY, Kim MJ, Jung MY, et al. Safety and efficacy of biodegradable microneedle acupuncture for dry eye: A multicenter, randomized, active-controlled pivotal trial. Integr Med Res. 2026. PMID: 42064363. doi:10.1016/j.imr.2026.101338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。